The challenge

Inhaling a drug is not as easy as taking a pill

Respiratory diseases are mainly treated with drugs, which are inhaled to the site of action, the lungs. At the same time, it is a challenge to get a grip of the complexity on this market, for physicians and patients. The variety of drugs/drug combinations and devices is so enormous, that even experts admit to struggle in keeping up with the development. Patients often feel left alone with the inhalation devices and the different drugs to use.

Training and adherence to therapy improves outcome for patients

The prevalence of Asthma is being estimated to 235 million patients in the US and Europe, resulting in a market of just over $17 billion. The prevalence of COPD is being estimated to 200 million patients, resulting in a market of just over $12 billion.
Non-adherence in chronic diseases increase double the cost of healthcare2 and increase hospitalization rate and mortality of patients significantly3.
Since inhaling drugs needs more training, not only adherence management will help respiratory patients, but extensive training is necessary.
So far, no player on the market focuses on training with included feedback to the patients.

Patients with pneumological diseases in the EU and worldwide

20M COPD patients in the EU
36M asthmatics in the EU
235M asthmatics worldwide
380M COPD patients worldwide

Therapy costs for pneumological diseases in Europe: € 82.3 billion

17% COPD indirectly
24% COPD directly
28% asthma directly
31% asthma indirectly
More about Kata

VisionHealth provides a solution for better health outcomes

VisionHealth is developing Kata® digital therapy support that not only promotes adherence, but also helps patients perform their therapy correctly.
Kata® will work for all types of inhaled drug devices.

With artificial intelligence, we will be able to give patients feedback on inhalation and make treatment more successful.

Kata® will help patients lead a life with fewer symptoms and without being affected by the chronic disease.

More about VisionHealth